Jada Bafus told Page Six that she and the actress quickly came to realize it was a case of “two triggered mothers” having a ...

Swank allegedly accused a mom taking her two terminally ill sons on a trip to Disneyland of snapping her picture at the ...

Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy, challenger from Massachusetts biotech Dyne ...

The Muscular Dystrophy Association (MDA) today announced more than $2.7 million in new research grants to advance groundbreaking discoveries across multiple neuromuscular diseases, including ...

The mother of two terminally ill boys has opened up about making peace with Oscar winner Hilary Swank following an alleged ...

Capricor Therapeutics said Wednesday that its cell therapy significantly improved muscle and heart function in patients with ...

Shares quadrupled now that the company appears on track to reverse an earlier FDA rejection of what could be the first ...

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, ...

Capricor stock skyrocketed to an eight-year high Wednesday, catapulting more than 300%, on positive results for its Duchenne ...

Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated ...

Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of ...